青少年和青年霍奇金淋巴瘤的管理:疾病负担还是选择负担?
青少年和青年(AYA)是霍奇金淋巴瘤(HL)受累的最大年龄组,治疗进展使总生存率良好,但治疗相关远期效应仍是生存者关注重点。自1964年首个HL化疗临床试验以来,后续方案试图减少化疗毒性并维持高总生存率。累积疾病负担等新分析方法可用于指导未来方案,但AYA人群面临诸多照护障碍且最不可能入组临床试验。
要点
- AYA是HL最大受累年龄组,治疗进展带来良好总生存率,但远期效应仍是生存者关注重点。
- 自1964年首个HL化疗试验以来,后续方案试图减少化疗毒性并维持高总生存率。
- AYA人群面临诸多照护障碍,最不可能入组临床试验;理论上可选择儿科或成人方案。
核心结论
- AYA霍奇金淋巴瘤患者总生存率良好,但治疗相关远期效应仍是生存者关注重点。
- 累积疾病负担等新分析方法可用于指导未来方案调整。
- 近期国家临床试验网络、儿童肿瘤学组等已努力确保AYA人群的选择负担不大于疾病负担。
研究设计与样本
- 综述;检索范围原文未报告。
主要发现
- AYA是霍奇金淋巴瘤最大受累年龄组。
- 自1964年首个霍奇金淋巴瘤化疗临床试验以来,后续方案试图减少化疗毒性并维持高总生存率。
- AYA人群在儿科与成人医疗服务之间被分割,面临诸多照护障碍,最不可能入组临床试验。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adolescents and young adults (AYAs) comprise the largest age group affected by Hodgkin lymphoma (HL). Despite excellent overall survival of AYA patients with HL due to advances in treatment regimens, therapy-associated late effects continue to be a concern in HL survivors, especially for younger patients who have decades of life remaining. Since the first clinical trial for HL with chemotherapy in 1964, subsequent protocols have attempted to reduce chemotherapy-induced toxicities and yet maintain high overall survival rates. Today, new analytic methods applied to data from survivorship cohorts, such as the recently described cumulative burden of disease metric, can be used to inform changes for future protocols. Although pediatric and adult trial consortia have followed this process, the AYA population, an age cohort split between pediatric and adult health care services, faces many barriers to care and is the least likely to be enrolled in clinical trials. AYA patients with HL theoretically have a choice to be treated in pediatric or adult protocols when presented with these options. Recent efforts by the National Clinical Trials Network, the Children's Oncology Group, and others have been made to ensure that the burden of choice for the AYA population is not greater than the burden of disease.
引用
- Flerlage JE, Metzger ML, Bhakta N, et al. The management of Hodgkin lymphoma in adolescents and young adults: burden of disease or burden of choice? Blood. 2018. PMID: 29895665. doi:10.1182/blood-2018-01-778548
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。